

Contains Nonbinding Recommendations
Draft Guidance on Trazodone Hydrochloride

This draft guidance, once finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

Active ingredient: Trazodone Hydrochloride

Form/Route: Tablet/Oral

Recommended studies: 2 studies

1. Type of study: Fasting
Design: Single-dose, two-way crossover *in-vivo*
Strength: 100 mg
Subjects: Healthy males and nonpregnant females under 65 years old
Additional Comments: Due to safety concerns, the study should be conducted using the 100 mg strength. The following special considerations are recommended for the enrollment criteria of healthy volunteers in the bioequivalence study:
 - Exclude any potential subject taking antihypertensive medications.
 - Prohibit concomitant administration ofazole antifungals, barbiturates, carbamazepine, central nervous system depressants, digoxin, HIV protease inhibitors, phenothiazines, phenytoin, SSRI antidepressants, and warfarin.
 - Prohibit all herbal preparations containing substances known to affect the cytochrome enzymes.
 - Prohibit alcohol in the study.

2. Type of study: Fed
Design: Single-dose, two-way crossover *in-vivo*
Strength: 100 mg
Subjects: Healthy males and nonpregnant females under 65 years old
Additional Comments: Please see comments above.

Analytes to measure (in appropriate biological fluid): Trazodone in plasma

Bioequivalence based on (90% CI): Trazodone

Waiver request of in-vivo testing: 50 mg, 150 mg and 300 mg based on (i) acceptable bioequivalence studies on the 100 mg strength, (ii) proportional similarity of the formulations across all strengths, and (iii) acceptable in vitro dissolution testing of all strengths.

Dissolution test method and sampling times:

Please note that a **Dissolution Methods Database** is available to the public at the OGD website at <http://www.accessdata.fda.gov/scripts/cder/dissolution/>. Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the application.